Major histocompatibility complex class I:Melanoma-associated antigen 1 peptide complex (MHC-I:MAGE-A1) (MHC-I:MAGE-A1)

The MHC-I:MAGE-1 peptide complex consists of a specific peptide fragment derived from the Melanoma-associated antigen 1 (MAGE-A1) protein presented on the cell surface by Major Histocompatibility Complex (MHC) Class I molecules, most commonly HLA-A1. MAGE-A1 is a member of the cancer-testis antigen (CTA) family, meaning it is highly expressed in various malignancies—including melanoma, lung cancer, and breast cancer—but is absent from healthy adult tissues, with the exception of immune-privileged germ cells in the testis. This restricted expression pattern makes the MHC-I:MAGE-1 complex an ideal target for highly specific cancer immunotherapies. Therapeutic strategies targeting this complex include the development of T-cell receptor (TCR) engineered T-cells and TCR-like antibodies that can recognize the intracellularly derived peptide when displayed on the cell surface. By binding specifically to the MAGE-1 peptide in the context of MHC-I, these therapies can trigger a potent cytotoxic immune response against tumor cells while sparing normal somatic tissues. Clinical development in this area focuses on ensuring high affinity for the target complex while minimizing cross-reactivity with similar peptides found in vital organs, a challenge highlighted by previous trials involving other MAGE family members.

Other names

HLA-A1:MAGE-A1 complexMAGE-A1/HLA-A1 complexMelanoma antigen family A 1 peptide-MHC complexpMHC MAGE-A1MAGE-1/HLA-A1

Targeting of the peptide-MHC complex by engineered T-cell receptors (TCRs) or TCR-like antibodies to induce T-cell mediated lysis of tumor cells.